Creative Planning’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Creative Planning’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,686	Closed	-$58.5K	–	3712
2024 Q3	$58.5K	Buy	+15,686	New	+$74.8K	﹤0.01%	3074
2016 Q4	–	Sell	-16	Closed	-$1K	–	4891
2016 Q3	$1K	Buy	+16	New	+$886	﹤0.01%	4465
2016 Q1	–	Sell	-503	Closed	-$45K	–	4578
2015 Q4	$45K	Sell	503 -50	-9%	-$3.95K	﹤0.01%	2199
2015 Q3	$41K	Buy	+553	New	+$46K	﹤0.01%	2184
2015 Q2	–	Sell	-426	Closed	-$18K	–	3141
2015 Q1	$18K	Buy	+426	New	+$12.1K	﹤0.01%	2808

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Creative Planning's EGRX Position: Q4 2024 in Review

Creative Planning sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 15,686 shares — an estimated $58.5K sold.

Creative Planning first reported a position in EGRX in Q1 2015 and held it in 5 quarters. The position peaked at $58.5K in Q3 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Creative Planning reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Creative Planning sold 15,686 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $58.5K.
Creative Planning first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
Creative Planning's Eagle Pharmaceuticals, Inc. position peaked at $58.5K in Q3 2024.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Creative Planning's 13F filing for Q4 2024, filed 14 Feb 2025.